Skip to main content
Smart Investors Daily
TE

NASDAQ · TECX

Tectonic Therapeutic, Inc.

Healthcare · Biotechnology

$20.98

Down-$0.16 (-0.76%)

Updated Nov 17, 2026, 9:56 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
364.22M
P/E ratio
-5.41
Dividend yield
0.00%
52-week range
$18.54 – $39.53
Volume
237.43K
Avg. volume
513.83K

Price performance · TECX

TECX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

TECX closed at $20.98 after 21 trading sessions, down 0.80% for the selected period.

Last close
$20.98
Period change
-0.80%
Period low
$18.98
Period high
$21.97
Daily close
View OHLC price history
TECX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$21.07$21.415$20.53$20.98237.43K
Nov 13, 2026$20.96$21.29$20.1101$21.14300.64K
Nov 12, 2026$21.75$21.75$20.20$21.04121.95K
Nov 11, 2026$22.19$22.49$21.73$21.96134.22K
Nov 10, 2026$21.82$22.80$21.14$21.97192.79K
Nov 9, 2026$21.18$22.09$20.28$21.89129.56K
Nov 6, 2026$19.00$20.89$18.92$20.64310.82K
Nov 5, 2026$20.30$20.30$19.00$19.42109.57K
Nov 4, 2026$19.57$20.565$19.33$20.30221.54K
Nov 3, 2026$19.13$19.74$18.76$18.98198.95K
Nov 2, 2026$19.78$19.94$18.535$18.98183.87K
Oct 30, 2026$20.51$20.51$19.56$19.78146.26K
Oct 29, 2026$20.92$21.44$20.355$20.50139.59K
Oct 28, 2026$20.12$20.77$19.99$20.56215.89K
Oct 27, 2026$20.09$20.54$19.735$20.34226.97K
Oct 26, 2026$20.00$20.5195$19.75$19.95151.22K
Oct 23, 2026$21.03$22.31$19.8301$20.07144.97K
Oct 22, 2026$21.86$22.275$20.97$21.09251.38K
Oct 21, 2026$21.86$22.30$21.53$21.84152.83K
Oct 20, 2026$21.22$22.44$20.99$21.825144.52K
Oct 19, 2026$20.78$21.2999$20.45$21.15202.97K

Latest TECX news

The latest Smart Investors Daily articles mentioning TECX.

TECX research

Overview

Company profile and research snapshot.

Company profile

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TECX recent ratings
DateFirmRatingTarget
Oct 12, 2026UBSNeutral—
Aug 7, 2026Wells FargoOverweight—
May 26, 2026Raymond JamesStrong Buy—
Apr 14, 2026StifelBuy—
Jan 8, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

Tectonic Therapeutic to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will participate in fireside chats at the upcoming Stifel 2026 Healthcare Conference, and the Piper Sandler 38th Annual Healthca

Yahoo · Nov 5, 2026

Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights

Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 Fast Track designation for Hereditary Hemorrhagic Telangiectasia (“HHT”) in September 2026 and cleared the Investigational New Drug (“IND”) application in August 2026 for the planned Phase 1b clinical trialDosed first patient in the ALPINE Phase 2a clinical trial of TX45 in pulmonary hypertension as

Benzinga · Nov 5, 2026

Tectonic Therapeutic Q3 EPS $(1.08) Beats $(1.33) Estimate

Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.33) by 18.8 percent. This is a 5.88 percent decrease over losses of $(1.02) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.